Jason Agulnik
Overview
Explore the profile of Jason Agulnik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fnais N, Laxague F, Mascarella M, Chowdhury R, Zhao H, Jatana S, et al.
JAMA Otolaryngol Head Neck Surg
. 2025 Mar;
PMID: 40048159
Importance: Patients with head and neck squamous cell cancer (HNSCC) are at a greater risk of developing pulmonary metastases and/or second primary lung cancer. However, it remains uncertain whether lung...
2.
Samaha R, El Sayed R, Alameddine R, Florescu M, Tehfe M, Routy B, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996857
Lung cancer remains the leading cause of cancer mortality globally with EGFR mutations representing a significant driver in advanced non-small cell lung cancer (aNSCLC). The timely detection of these mutations...
3.
Ramasamy G, Muanza T, Kasymjanova G, Agulnik J
Cureus
. 2025 Jan;
16(12):e75819.
PMID: 39816274
Background A minority of patients receiving stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) are not good responders. Radiomic features can be used to generate predictive algorithms...
4.
Cohen S, Cruiziat D, Naimer J, Cohen V, Kasymjanova G, Spatz A, et al.
Curr Oncol
. 2024 Nov;
31(11):7379-7389.
PMID: 39590174
Background: Immunotherapy with ICIs has revolutionized the treatment for NSCLC. The impact of sex on treatment outcomes remains unclear. The aim of this study was to evaluate sex-related differences in...
5.
Barghout S, Zhan L, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, et al.
Lung Cancer
. 2024 Jul;
194:107898.
PMID: 39074423
Objectives: KRAS mutations, particularly KRAS, are prevalent in non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have been a frontline treatment, but recently developed KRAS-selective inhibitors, such as sotorasib,...
6.
Agulnik J, Kasymjanova G, Pepe C, Friedmann J, Small D, Sakr L, et al.
Curr Oncol
. 2024 Mar;
31(3):1562-1571.
PMID: 38534952
The effect of COVID-19 on treatment outcomes in the literature remains limited and is mostly reported either as predictive survival using prioritization and modeling techniques. We aimed to quantify the...
7.
Pilon Y, Rokah M, Seitlinger J, Sepesi B, Rayes R, Cools-Lartigue J, et al.
Clin Lung Cancer
. 2024 Feb;
25(3):e133-e144.e4.
PMID: 38378398
Background: Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III of non-small cell lung cancer (NSCLC) and numerous trials investigating novel agents...
8.
Chen Y, MacIsaac S, Young M, Ahodakin M, Jeagal L, Boucher M, et al.
CMAJ
. 2024 Feb;
196(6):E177-E186.
PMID: 38378218
Background: Whether Inuit in Canada experience disparities in lung cancer survival remains unknown. When requiring investigation and treatment for lung cancer, all residents of Nunavik, the Inuit homeland in Quebec,...
9.
Bierbrier R, DAguanno K, Kasymjanova G, DellAniello S, Agulnik J, Pehr K
J Am Acad Dermatol
. 2022 Oct;
88(4):869-870.
PMID: 36228936
No abstract available.
10.
Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, et al.
Eur J Cancer
. 2020 Nov;
142:83-91.
PMID: 33242835
Background: The PACIFIC trial demonstrated that durvalumab therapy following chemoradiation (CRT) was associated with improved overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC). It is...